Stilla Technologies

Digital PCR Technology

Stilla Technologies is developing technology to accelerate the generation of next-generation genetic testing. Precise genetic analysis solutions have the capacity to enhance human health. Stilla is focusing on multiplex digital PCR to transform complex genomic data into actionable insights across a wide range of research and clinical applications, from cancer and liquid biopsy studies, to cell and gene therapies and environmental testing. Stilla’s lead product, Nio system, uses their groundbreaking crystal digital PCR solution featuring six fluorescent channels, providing researchers and clinicians with the highest multiplexing and detection capacity available.